Unprecedented momentum is building in 2025:

• Kriya Therapeutics are advancing through their preclinical development

• Opus Genetics and SpliceBio have entered their early trials

• Ocugen, 4D Molecular Therapeutics, and AbbVie race towards BLA approval

This surge creates an urgent demand to mitigate critical bottlenecks like endpoints, funding, delivery, and more.

The 6th Gene Therapy for Ophthalmic Disorders Summit returns in Raleigh, North Carolina, as the leading industry-specific event uniting biopharma scientists and strategists to tackle these developmental challenges head-on.

Join to unlock the next breakthrough beyond Luxturna and accelerate your therapy to patients.

View the event here.